| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ... Leukemia 29 (10), 2062-2068, 2015 | 590 | 2015 |
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease S Spoerl, NR Mathew, M Bscheider, A Schmitt-Graeff, S Chen, T Mueller, ... Blood, The Journal of the American Society of Hematology 123 (24), 3832-3842, 2014 | 427 | 2014 |
| Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation M Mavers, K Maas-Bauer, RS Negrin Frontiers in immunology 8, 284778, 2017 | 66 | 2017 |
| DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease H Nishikii, BS Kim, Y Yokoyama, Y Chen, J Baker, A Pierini, M Alvarez, ... Blood, The Journal of the American Society of Hematology 128 (24), 2846-2858, 2016 | 46 | 2016 |
| Ruxolitinib–ECP combination treatment for refractory severe chronic graft-versus-host disease K Maas-Bauer, C Kiote-Schmidt, H Bertz, P Apostolova, R Wäsch, G Ihorst, ... Bone marrow transplantation 56 (4), 909-916, 2021 | 35 | 2021 |
| Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming F Simonetta, JK Lohmeyer, T Hirai, K Maas-Bauer, M Alvarez, ... Clinical Cancer Research 27 (21), 6054-6064, 2021 | 31 | 2021 |
| Activation of the DR3-TL1A axis in donor mice leads to regulatory T cell expansion and activation with reduction in graft-versus-host disease M Mavers, F Simonetta, H Nishikii, JV Ribado, K Maas-Bauer, M Alvarez, ... Frontiers in immunology 10, 462994, 2019 | 21 | 2019 |
| Long-term follow-up of patients with corticosteroid-refractory graft-versus-host disease treated with ruxolitinib R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, S Metzelder, ... Blood 128 (22), 4561, 2016 | 20 | 2016 |
| Invariant natural killer T-cell subsets have diverse graft-versus-host-disease–preventing and antitumor effects K Maas-Bauer, JK Lohmeyer, T Hirai, TL Ramos, FM Fazal, ... Blood, The Journal of the American Society of Hematology 138 (10), 858-870, 2021 | 14 | 2021 |
| Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD T Hirai, PY Lin, F Simonetta, K Maas-Bauer, M Turkoz, M Mavers, J Baker, ... Blood advances 5 (11), 2528-2538, 2021 | 9 | 2021 |
| High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers R Zeiser, C Lengerke, S Spoerl, K Maas-Bauer, M Ditschkowski, M Ecsedi, ... Bone Marrow Transplant. 50, S22-1, 2015 | 7 | 2015 |
| Treatment of corticosteroid-refractory graft-versus-host disease with ruxolitinib in 95 patients R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, S Metzelder, ... Blood, The Journal of the American Society of Hematology 126 (23), 858-858, 2015 | 6 | 2015 |
| Infusion of host-derived unlicensed NK cells improves donor engraftment in non-myeloablative allogeneic hematopoietic cell transplantation M Alvarez, A Pierini, F Simonetta, J Baker, K Maas-Bauer, T Hirai, ... Frontiers in Immunology 11, 614250, 2021 | 5 | 2021 |
| Response to JAK 1/2 inhibition in patients with corticosteroid-refractory acute graft-versus-host disease S Spoerl, K Maas-Bauer, M Verbeek, P Apostolova, AL Illert, N Mathew, ... Blood 124 (21), 3934, 2014 | 5 | 2014 |
| Diagnostik und moderne Behandlungsstrategien: Multiples Myelom J Schnerch, M Kleber, K Maas-Bauer, G Herget, K Henne, T Baumann, ... Im Focus Onkologie 17, 56-63, 2014 | 3 | 2014 |
| Distinct immune regulatory potential of invariant natural killer T (iNKT) cell subsets: iNKT2 and iNKT17, but not iNKT1, protect from graft-versus-host-disease F Simonetta, K Maas-Bauer, T Hirai, A Wenokur, FM Fazal, N Kambham, ... Biology of Blood and Marrow Transplantation 25 (3), S1-S2, 2019 | 2 | 2019 |
| Ruxolitinib for corticosteroid-refractory graft-versus-host disease: analysis of 95 patients treated at multiple medical centers R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, S Metzelder, ... Oncol. Res. Treat. 38, 43-45, 2015 | 2 | 2015 |
| Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells K Maas-Bauer, N Köhler, AV Stell, M Zwick, S Acharya, A Rensing-Ehl, ... Journal of Leukocyte Biology 115 (2), 401-409, 2024 | 1 | 2024 |
| Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature … P Apostolova, S Kreutmair, C Toffalori, M Punta, S Unger, AC Burk, ... British Journal of Haematology 203 (2), 264-281, 2023 | 1 | 2023 |
| Allogeneic chimeric antigen receptor-invariant natural killer T cells exert both direct and indirect antitumor effects through host CD8 T cell cross-priming F Simonetta, T Hirai, JK Lohmeyer, K Maas-Bauer, M Alvarez, A Wenokur, ... Biology of Blood and Marrow Transplantation 26 (3), S42, 2020 | 1 | 2020 |
